Compare LOAN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | ATNM |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 31.4M |
| IPO Year | 1999 | 2013 |
| Metric | LOAN | ATNM |
|---|---|---|
| Price | $3.29 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 24.3K | ★ 268.1K |
| Earning Date | 10-21-2026 | 11-27-2026 |
| Dividend Yield | ★ 13.71% | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | 0.32 | ★ 0.71 |
| Revenue | ★ $8,666,307.00 | $90,000.00 |
| Revenue This Year | N/A | $38,788.89 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.05 | ★ $2.31 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.19 | $0.74 |
| 52 Week High | $5.01 | $1.72 |
| Indicator | LOAN | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 54.93 |
| Support Level | N/A | $0.97 |
| Resistance Level | $4.50 | $1.53 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.72 | 51.90 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.